Clinical scenarios were developed to mimic patient presentations encountered in everyday practice. These scenarios included information on symptom status; risk level as assessed by noninvasive testing; coronary disease burden; and, in some scenarios, fractional flow reserve testing, presence or absence of diabetes, and SYNTAX score.
This update provides a reassessment of clinical scenarios that the writing group felt were affected by significant changes in the medical literature or gaps from prior criteria.
The methodology used in this update is similar to the initial document but employs the recent modifications in the methods for developing AUC, most notably, alterations in the nomenclature for appropriate use categorization.
A separate, independent rating panel scored the clinical scenarios on a scale of 1 to 9. Scores of 7 to 9 indicate that revascularization is considered appropriate for the clinical scenario presented. Scores of 1 to 3 indicate that revascularization is considered rarely appropriate for the clinical scenario, whereas scores in the mid-range of 4 to 6 indicate that coronary revascularization may be appropriate for the clinical scenario.
As seen with the prior coronary revascularization AUC, revascularization in clinical scenarios with high symptom burden, high-risk features, and high coronary disease burden, as well as in patients receiving antianginal therapy, are deemed appropriate. Additionally, scenarios assessing the appropriateness of revascularization before kidney transplantation or transcatheter valve therapy are now rated. The primary objective of the AUC is to provide a framework for the assessment of practice patterns that will hopefully improve physician decision making. The AUC provide a practical standard upon which to assess and better understand variability.
We are grateful to the writing committee for the development of the overall structure of the document and clinical scenarios and to the rating panel-a professional group with a wide range of skills and insights-for their thoughtful deliberation on the merits of coronary revascularization for various clinical scenarios. We would also like to thank the parent AUC Task Force and the ACC staff-Joseph Allen, Leah White, and specifically, Maria Velasquez-for their skilled support in the generation of this document. Additional studies, some based on data from the National Cardiovascular Data Registry (NCDR), have been published providing insights into practice patterns and information around clinical scenarios and patient features not previously addressed (9-13).
Improvements in our understanding of the variables affecting patient outcomes before and after coronary revascularization, continued emphasis on the role of medical therapy for coronary artery disease (CAD), and an increasing emphasis on shared decision making and patient preferences also make a revision of the coronary revascularization AUC timely (14). This document focuses on SIHD and is a companion to the AUC specifically for acute coronary syndromes.
METHODS

Indication Development
A multidisciplinary writing group consisting of cardiovascular health outcomes researchers, interventional cardiologists, cardiothoracic surgeons, and general cardiologists was convened to review and revise the prior coronary revascularization AUC. The writing group was tasked with developing clinical indications (scenarios) that reflect typical situations encountered in everyday practice that were then rated by a technical panel. In this document, the term "indication" is used interchangeably with the phrase "clinical scenario." Critical data elements and mapping of the criteria to the elements will be provided for end-users of the revascularization AUC so that procedure notes and chart abstraction can be more easily mapped to the AUC. A key goal of this effort is to leverage the NCDR (National Cardiovascular Data Registry) Cath-PCI registry to map indications to appropriateness ratings, so that minimal additional data collection is needed to support quarterly feedback to sites of their performance as a foundation for improving patient selection for revascularization. The AUC Task Force is committed to supporting linkage of the AUC with daily workflow to capture the data elements needed for AUC ratings.
The revascularization AUC are based on our current understanding of procedure outcomes plus the potential patient benefits and risks of the revascularization strategies examined. Although the AUC are developed to address many of the common clinical scenarios encountered in practice, it would be impossible to include every conceivable patient presentation and maintain a workable document for clinicians. The writing group acknowledges that the current AUC do not evaluate all patient variables that might affect 1 or more strategies for the management of patients with CAD. Examples of conditions not explicitly considered within the scenarios include severe chronic kidney disease, severe peripheral vascular disease, known malignancies, poor lung function, advanced liver disease, advanced dementia, and/or other comorbidities that might have excluded patients from the clinical trials that provide the evidence base for coronary revascularization. Nevertheless, it is necessary for the clinician to include these conditions in the final decision-making process for an individual patient, and this may result in the actual therapy deviating from the AUC rating. It is expected that all clinicians will occasionally treat patients with extenuating conditions that are not captured in the current AUC, and this could result in a treatment rating of "rarely appropriate" for the chosen therapy in a specific patient. However, these situations should not constitute a majority of treatment decisions, and it is presumed that they will affect all practitioners equally, thereby minimizing substantial biases in assessing the performance of individual clinicians compared with their peers. Additionally, these AUC were developed in parallel with efforts to update data collection within the NCDR registries to include data fields that capture some of these extenuating circumstances, thereby improving the characterization of scenarios in the AUC.
AUC documents often contain specific clinical scenarios rather than the more generalized situations covered in CPGs; thus, subtle differences between these documents may exist. The treatment of patients with SIHD should always include therapies to modify risk factors and/or reduce cardiovascular events-so-called secondary prevention. In several CPGs, the phrase "guideline-directed medical therapy" is used and, depending on the context, may include the use of antianginal therapy in addition to therapies for secondary prevention. In this AUC, it is assumed that all patients will be receiving comprehensive secondary prevention therapies as needed. Antianginal therapy has a central role in the treatment of patients with SIHD. In some patients, it may be the sole therapy, whereas in others it may be continued, albeit in lower doses, following a revascularization procedure. The earlier coronary revascularization AUC included information about the intensity of antianginal therapy in several scenarios, with language such as "receiving no or minimal anti-ischemic therapy" or "receiving a course of maximal anti-ischemic therapy."
The new AUC adopts a different format, including options for the initiation or escalation of antianginal therapy In rating these criteria, the rating panel was asked to assess whether the use of revascularization for each indication is "appropriate care," "may be appropriate care," or is "rarely appropriate care" using the following definitions and their associated numeric ranges. Anonymized individual scores are available in an online appendix.
Median Score 7 to 9: Appropriate Care
An appropriate option for management of patients in this population, as the benefits generally outweigh the risks;
an effective option for individual care plans, although not always necessary depending on physician judgment and patient-specific preferences (i.e., procedure is generally acceptable and is generally reasonable for the indication).
Median Score 4 to 6: May Be Appropriate Care
At times an appropriate option for management of patients in this population due to variable evidence or agreement regarding the benefit to risk ratio, potential benefit based on practice experience in the absence of evidence, and/or variability in the population; effectiveness for individual care must be determined by a patient's physician in consultation with the patient on the basis of additional clinical variables and judgment along with patient preferences (i.e., procedure may be acceptable and may be reasonable for the indication).
Median Score 1 to 3: Rarely Appropriate Care
Rarely an appropriate option for management of patients in this population due to the lack of a clear benefit/risk advantage; rarely an effective option for individual care plans; exceptions should have documentation of the clinical reasons for proceeding with this care option (i.e., procedure is not generally acceptable and is not generally reasonable for the indication).
The process for development of the AUC is shown in Figure 1 and described in detail in previous documents
(1,2).
After completion and tabulation of the second round of ratings, it became apparent to the writing group that the original structure of certain rating tables may have confused some members of the rating panel, causing ratings that were not internally consistent. This resulted in a re-evaluation and redesign of the rating table structure, which then required a third round of ratings. This AUC document presents the end result of that process and the results of the third round of ratings.
Scope of Indications
The indications for coronary revascularization in SIHD were developed considering the following common variables: 
ASSUMPTIONS
General Assumptions
Specific assumptions 4. Assume no other significant coronary artery stenoses are present except those specifically described in the clinical scenario.
A significant coronary stenosis for the purpose of the clinical scenarios is defined as:
n $70% luminal diameter narrowing, by visual assessment, of an epicardial stenosis measured in the "worst view" angiographic projection;
n $50% luminal diameter narrowing, by visual assessment, of a left main stenosis measured in the "worst view" angiographic projection; or n 40% to 70% luminal narrowing, by visual assessment, of an epicardial stenosis measured in the "worst view" angiographic projection with an abnormal FFR as defined in the following text.
6. An FFR #0.80 is abnormal and is consistent with downstream inducible ischemia.
7. All patients included in these scenarios are receiving needed therapies to modify existing risk factors as outlined in CPGs and other documents (17) (18) (19) . Despite the best efforts of the clinician, all patients may not achieve target goals for cardiac risk factor modification. However, a continuing effort and plan of care to address risk factors are assumed to exist. asymptomatic patients are truly asymptomatic rather
Patel et al. treatment or even all treatments may be considered "Appropriate," "May Be Appropriate," or "Rarely
Appropriate" for any given clinical indication.
2. If more than 1 treatment falls into the same appropriate use category, it is assumed that patient preference combined with physician judgment and available local expertise will be used to determine the final treatment used.
DEFINITIONS
Definitions of some key terms used throughout the scenarios are shown in the following text. A complete set of definitions is found in Appendix A. These definitions were provided to and discussed with the rating panel before the rating process started.
Indication
A set of patient-specific conditions defines an "indica- Specific target doses of drugs are not provided as this must be individualized, but for beta blockers, it is assumed the dose is sufficient to blunt the exercise heart rate without causing intolerable fatigue, bradycardia, or hypotension. It is assumed that the maximally tolerated dose of beta blockers is being used before the addition of other drugs, and when other drugs are added, the dose is titrated to alleviate symptoms or is also the maximally tolerated dose. Using multiple drugs at less than optimal doses is an inefficient and expensive strategy. The SIHD guideline recommends calcium channel blockers or longacting nitrates if beta blockers are contraindicated or cause unacceptable side effects. The SIHD guideline also recommends adding calcium channel blockers or longacting nitrates to beta blockers for relief of symptoms when initial treatment with beta blockers is unsuccessful. 
Vessel Disease
The construct used to characterize the extent of CAD is based on the common clinical use of the terms 1-, 2-, and 3-vessel disease and left main disease, although it is recognized that individual coronary anatomy is highly variable.
In general, these terms refer to a significant stenosis in 1 of the 3 major coronary arteries (right coronary artery, LAD, or circumflex) or their major branches. With the exception of the proximal LAD, which specifically refers to the segment of the LAD proximal to the first major septal and diagonal, the terms 1-, 2-, and 3-vessel disease do not define the location (i.e., proximal, mid, or distal) of the stenosis in the artery, which is frequently related to the amount of myocardium at risk. Furthermore, the classification of 
AUC for Coronary Revascularization in Patients With SIHD -, 2017:---
Ischemic Symptoms
Angina pectoris is usually described as a discomfort (not necessarily pain) in the chest or adjacent areas. It is variably described as tightness, heaviness, pressure, squeezing, or a smothering sensation. In some patients, the symptom may be a more vague discomfort, a numbness, or a burning sensation. Alternatively, so- Resting perfusion abnormalities $10% of the myocardium in patients without prior history or evidence of MI 3. Stress ECG findings including $2 mm of ST-segment depression at low workload or persisting into recovery, exercise-induced ST-segment elevation, or exercise-induced VT/VF 4. Severe stress-induced LV dysfunction (peak exercise LVEF <45% or drop in LVEF with stress $10%) 5. Stress-induced perfusion abnormalities encumbering $10% myocardium or stress segmental scores indicating multiple vascular territories with abnormalities 6. Stress-induced LV dilation 7. Inducible wall motion abnormality (involving >2 segments or 2 coronary beds) 8. Wall motion abnormality developing at low dose of dobutamine (#10 mg/kg/min) or at a low heart rate (<120 beats/min) 9. CAC score >400 Agatston units 10. Multivessel obstructive CAD ($70% stenosis) or left main stenosis ($50% stenosis) on CCTA Intermediate risk (1% to 3% annual death or MI) 1. Mild/moderate resting LV dysfunction (LVEF 35% to 49%) not readily explained by noncoronary causes 2. Resting perfusion abnormalities in 5% to 9.9% of the myocardium in patients without a history or prior evidence of MI 3. $1 mm of ST-segment depression occurring with exertional symptoms 4. Stress-induced perfusion abnormalities encumbering 5% to 9.9% of the myocardium or stress segmental scores (in multiple segments) indicating 1 vascular territory with abnormalities but without LV dilation 5. Small wall motion abnormality involving 1 to 2 segments and only 1 coronary bed 6. CAC score 100 to 399 Agatston units 7. One vessel CAD with $70% stenosis or moderate CAD stenosis (50% to 69% stenosis) in $2 arteries on CCTA Low risk (<1% annual death or MI) 1. Low-risk treadmill score (score $5) or no new ST segment changes or exercise-induced chest pain symptoms; when achieving maximal levels of exercise 2. Normal or small myocardial perfusion defect at rest or with stress encumbering <5% of the myocardium* 3. Normal stress or no change of limited resting wall motion abnormalities during stress 4. CAC score <100 Agaston units initial therapy should be a beta blocker prescribed at a dose that reduces heart rate without excessive resting bradycardia, hypotension, or fatigue. Other antianginal drugs are then added to beta blockers depending on the individual needs of the patient until symptoms are suppressed to the satisfaction of the patient or higher doses cannot be used because of side effects. In each of the subordinate columns, the panel was asked to rate the options for revascularization, specifically PCI or CABG. As noted earlier, the rating panel was asked to rate each revascularization option independent of the other, with the intent to rate each therapy on its own merits rather than in comparison to the other option. In this construct, both revascularization options could be assigned identical ratings.
In this and subsequent tables, clinical scenarios often contain the phrase "noninvasive testing." In this document, that phrase includes all forms of stress testing using either dynamic or pharmacological stress that may be coupled with various imaging tests. It also could include other imaging, such as coronary computed tomography angiography or magnetic resonance imaging, to assess 
2.
n Intermediate-or high-risk findings on noninvasive testing (5) A (7) A (7) 5. n Intermediate-or high-risk findings on noninvasive testing (6) A (7) A (7) A (8) A (8) 6. n No stress test performed or, if performed, results are indeterminate n FFR #0.80
The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR.
A indicates appropriate; AA, antianginal; BB, beta blockers; CABG, coronary artery bypass graft; FFR, fractional flow reserve; iFR, instant wave-free ratio; LAD, left anterior descending coronary artery; LCX, left circumflex artery; M, may be appropriate; PCI, percutaneous coronary intervention; and R, rarely appropriate.
formulating revascularization recommendations (35) . (2) M (4) R (3) M (5) M (4) A (7) M (6) 8. n Intermediate-or high-risk findings on noninvasive testing
M (5) M (4) M (6) M (5) A (7) M (6) A (8) A (7) 9.
n No stress test performed or, if performed, results are indeterminate n FFR #0.80* in both vessels M (5) M (4) M (6) M (4) A (7) M (5) A (8) A (7) Proximal LAD Involvement and No Diabetes Present
10.
n Low-risk findings on noninvasive testing M (4) M (4) M (5) M (5) M (6) M (6) A (7) A (7) 11. n Intermediate-or high-risk findings on noninvasive testing
M (6) M (6) A (7) A (7) A (7) A (7) A (8) A (8) 12.
n No stress test performed or, if performed, results are indeterminate n FFR #0.80 in both vessels M (6) M (6) M (6) M (6) A (7) A (7) A (8) A (8) Proximal LAD Involvement With Diabetes Present
13.
n Low-risk findings on noninvasive testing M (4) M (5) M (4) M (6) M (6) A (7) A (7) A (8) 14.
n Intermediate-or high-risk findings on noninvasive testing
M (5) A (7) M (6) A (7) A (7) A (8) A (8) A (9) 15. n No stress test performed or, if performed, results are indeterminate n FFR #0.80 in both vessels* M (5) M (6) M (6) A (7) A (7) A (8) A (7) A (8) The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR.
A indicates appropriate; AA, antianginal; BB, beta blockers; CABG, coronary artery bypass graft; FFR, fractional flow reserve; iFR, instant wave-free ratio; LAD, left anterior descending coronary artery; M, may be appropriate; PCI, percutaneous coronary intervention; and R, rarely appropriate. first modality to assess ambiguous left main severity, and the criteria for a significant stenosis are the same as for non-left main stenosis (21, 36, 37) . Although FFR measurements are well-validated in native vessels, data on the use of FFR in vein grafts are limited (38) . After CABG surgery, the bypass conduit should act in a similar fashion to the native, lowresistance epicardial vessel. However, the assessment of ischemia due to a stenosis in a vein graft is complicated by several features, which include: 1) the potential for competing flow (and pressure) from both the native and conduit vessels; 2) the presence of collaterals from longstanding native coronary occlusion; and 3) the potential for microvascular abnormalities due to ischemic fibrosis and scarring, pre-existing or bypass surgery-related myocardial infarction, or chronic lowflow ischemia. Despite these complicating features, the theory of FFR should apply equally to both a lesion in an SVG to the right coronary artery feeding a normal myocardial bed and a lesion in the native right coronary. However, if the native and collateral supply are sufficiently large, the FFR across an SVG stenosis could be normal. FFR measurements may be most useful in the setting of an occluded bypass graft to a (6) A (7) A (7) 17. n Intermediate-or high-risk findings on noninvasive testing n No diabetes M (6) A (7) A (7) A (7) A (7) A (8) A (8) A (8) 18. n Low-risk findings on noninvasive testing n Diabetes present (6) A (7) A (7) A (8) 19. n Intermediate-or high-risk findings on noninvasive testing n Diabetes present M (6) A (7) M (6) A (8) A (7) A (8) A (7) A (9) Intermediate or High Disease Complexity (e.g. Multiple Features of Complexity as Noted Previously, SYNTAX >22)
20.
n Low-risk findings on noninvasive testing n No diabetes (4) A (7) M (5) A (7) M (6) A (8) 21. n Intermediate-or high-risk findings on noninvasive testing n No diabetes M (5) A (7) M (6) A (7) M (6) A (8) M (6) A (9) 22. n Low-risk findings on noninvasive testing n Diabetes present
23. n Intermediate-or high-risk findings on noninvasive testing n Diabetes present
The number in parentheses next to the rating reflects the median score for that indication.
A indicates appropriate; AA, antianginal; BB, beta blockers; CABG, coronary artery bypass graft; M, may be appropriate; PCI, percutaneous coronary intervention; and SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery trial.
native artery with an intermediate-severity stenosis.
FFR measurements in bypass grafts are less wellvalidated and should thus be interpreted with caution.
Two tables are presented for the rating of patients with prior CABG depending on the patency of an existing internal mammary artery (IMA) graft. IMAs have a greater long-term patency rate than SVGs-typically >90% after 10 years (39, 40) . Accordingly, use of the IMA as a conduit in CABG surgery has steadily increased. Current use is Table 2 .1., it is assumed that the LAD was significantly diseased at the time of the original operation. Therefore, if the IMA to the LAD is no longer patent or is severely diseased, it is assumed that the native LAD is also severely diseased or occluded.
Section 3. Table 3 .1 SIHD Undergoing Procedures for Which
Coronary Revascularization May Be Considered
In an effort to capture common clinical scenarios that are not well-represented in guidelines, the writing group developed indications for preoperative revascularization in patients being evaluated for renal transplantation or structural heart procedures. The writing committee recognized that pre-operative revascularization is sometimes requested before transplantation of other organs, but there is insufficient experience or data from controlled studies upon which to develop meaningful scenarios. These scenarios do not capture all possible clinical situations, but were felt to capture the majority of (6) A (8) A (7) A (8) A (7) A (9) A (7) A (9) 25. n Isolated LMCA disease n Bifurcation involvement
26. n LMCA disease n Ostial or midshaft stenosis n Concurrent multivessel disease n Low disease burden (e.g., 1-2 additional focal stenoses, SYNTAX score #22)
M (6) A (8) M (6) A (9) A (7) A (9) A (7) A (9) 27. n Ostial or midshaft stenosis n Concurrent multivessel disease n Intermediate or high disease burden (e.g., 1-2 additional bifurcation stenosis, long stenoses, SYNTAX score >22)
M (4) A (9) M (4) A (9) M (4) A (9) M (4) A (9) 28. n LMCA disease n Bifurcation involvement n Low disease burden in other vessels (e.g., 1-2 additional focal stenosis, SYNTAX score #22)
29.
n LMCA disease n Bifurcation involvement n Intermediate or high disease burden in other vessels (e.g., 1-2 additional bifurcation stenosis, long stenoses, SYNTAX score >22)
A indicates appropriate; AA, antianginal; BB, beta blockers; CABG, coronary artery bypass graft; LMCA, left main coronary artery; M, may be appropriate; PCI, percutaneous coronary intervention; R, rarely appropriate; and SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery trial. common clinical situations. If patients have an acute coronary syndrome, the writing group felt they should be rated according to the AUC for acute coronary syndrome. For many of these patients, symptoms may be difficult to attribute to myocardial ischemia; thus, the indications used in this table provide only anatomic and noninvasive test findings for review. Note that for patients being evaluated before a percutaneous valve procedure, the option for CABG surgery is blocked out, as it is assumed such patients have clinical factors making their risk of surgery prohibitively high.
DISCUSSION
The AUC are intended to inform clinicians, patients, and 
30.
n Low-risk findings on noninvasive testing
31.
32.
n No stress test performed or, if performed, the results are indeterminate n FFR of stenosis #0.80*
Stenoses Supplying 2 Territories (Bypass Graft or Native Artery, Either 2 Separate Vessels or Sequential Graft Supplying 2 Territories) Not Including Anterior Territory
33.
34.
n Intermediate-or high-risk findings on noninvasive testing (4) A (7) M (5) A (8) M (6) The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR.
A indicates appropriate; AA, Antianginal; BB, beta blockers; CABG, coronary artery bypass graft; FFR, fractional flow reserve; iFR, instant wave-free ratio; IMA, internal mammary artery; LAD, left anterior descending coronary artery; M, may be appropriate; PCI, percutaneous coronary intervention; and R, rarely appropriate.
(e.g., single-vessel disease), low-risk findings on noninvasive testing, and/or no antianginal therapy, revascularization by PCI or CABG surgery for care is felt to be rarely appropriate as the initial step. As disease burden progresses through 2-vessel to 3-vessel and left main disease, revascularization by PCI or CABG frequently becomes rated as "may be appropriate care" or "appropriate care," with CABG surgery consistently rated as "appro- Repeat CABG surgery was felt to be rarely appropriate in patients with a functional patent IMA to the LAD in all but 1 indication, with both PCI and CABG being rated as either "may be appropriate care" or "appropriate care" in the other indications, reflecting the complex and individualized decision making required in these patients.
With the exception of a few specific scenarios in asymptomatic patients with a low disease burden, revascularization options were considered as "may be appropriate care" or "appropriate care" options. Although not directly rated, the use of fractional flow reserve for evaluation of renal transplant patients may be considered and will be addressed in future revascularization documents. Revascularization by PCI was considered appropriate care for the majority of patients being evaluated before a percutaneous valve procedure.
Application of Criteria
There are many potential applications for AUC, including their adoption by Centers for Medicare & Medicaid Services regulators as a means of evaluating care. Clinicians can use the ratings for decision support or as an educational tool when considering the need for revascularization. Moreover, these criteria can be used to facilitate discussions with patients and/or referring physicians about the need for revascularization. The original intent of the AUC was to provide a tool to identify patterns of care, including both the overuse and underuse of various services. In fact, some of the initial publications related to AUC identified underuse and the consequences of underuse rather than overuse of services (42, 43) . Facilities have used these criteria to design protocols to facilitate the appropriate care of patients. Some payers have adopted the AUC for use in the preauthorization of procedures or retrospectively for quality reports. Although the AUC were never intended to determine payment in individual patients, some payers have adopted the AUC for this purpose. The desire of payers to control costs is understood, but it should be in the context of developing rational payment management strategies to ensure their members receive necessary, beneficial, and cost-effective cardiovascular care, rather than for other purposes. It is expected that services performed for "appropriate" or M (6) A (7) A (7) A (7) A (7) A (7) A (8) A (8) 47.
n Left main and/or three-vessel disease, with intermediate-or high-risk noninvasive findings (e.g., SYNTAX >22)
Patients Undergoing Renal Transplantation, Diabetes Present
48.
n One-or two-vessel CAD, no proximal LAD involvement, with low-risk noninvasive findings
49.
n One-or two-vessel CAD, no proximal LAD involvement, with intermediate-or high-risk noninvasive findings
50. n One-or two-vessel CAD, including proximal LAD, with low-risk noninvasive findings 
A indicates appropriate; AA, Antianginal; BB, beta blockers; CABG, coronary artery bypass graft; CAD, coronary artery disease; LAD, left anterior descending coronary artery; M, may be appropriate; PCI, percutaneous coronary intervention; R, rarely appropriate; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery trial; and TAVR, transcatheter aortic valve replacement. In conclusion, this document represents the current understanding of the clinical benefit of coronary revascularization with respect to health outcomes and survival.
These criteria have been developed through the AUC process and alignment with the evidence and recommendations from clinical practice guidelines. This is intended to provide a practical guide to clinicians and patients when considering revascularization. As with all AUC, some of these ratings will require research and further evaluation to provide the greatest information and benefit to clinical decision making. We anticipate that the utility and ability of these criteria to improve the quality of care will be measured by the overall use and adoption of the criteria.
With each update, the AUC for coronary revascularization in SIHD have become more refined and specific, while areas for continued focus and research have been identified. 
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